Pharmacokinetics , Dosimetry , and Initial Therapeutic Results with 131 I-and lllIn-/ 9 ~ Humanized LL 2 Anti-CD 22 Monoclonal Antibody in Patients with Relapsed , Refractory Non-Hodgkin ' s Lymphoma

M a l i k E. J u w e i d , 2 E d w a r d S t a d t m a u e r , G e o r g e H a j j a r , R o b e r t M . S h a r k e y , S a m e r S u l e i m a n , S e l i n a L u g e r , L a w r e n c e C. S w a y n e , A b a s s A l a v i , a n d D a v i d M . G o l d e n b e r g Garden State Cancer Center, Belleville, New Jersey 07109 [M. E. J., R. M. S., G. H., S. S., L. C. S., D. M. G.], and the Hospital of the University of Pennsylvania, Philadelphia, Pennsylvania 19104 [g. S., S.L., a . a . ]